Skip to main content
Sage grants Shionogi exclusive rights to MDD drug in 3 countries
6/19/2018

Sage Therapeutics granted Shionogi exclusive rights to develop and commercialize major depressive disorder drug candidate SAGE-217 in Japan, South Korea and Taiwan. Sage will get an upfront payment of $90 million and up to $485 million for milestones plus royalty fees.

Full Story: